US Bancorp
KYTX icon

US Bancorp’s Kyverna Therapeutics KYTX Stock Holding History

US Bancorp’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$809 Buy
+119
New +$939 ﹤0.01% 4073
2025
Q1 		– Sell
-4,600
Closed -$17.2K – 4381
2024
Q4 		$17.2K Buy
4,600
+4,431
+2,622% +$21.2K ﹤0.01% 3223
2024
Q3 		$826 Buy
+169
New +$1.3K ﹤0.01% 3913

Other funds holding KYTX

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ACPLP
ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

US Bancorp's KYTX Position: Q3 2026 in Review

US Bancorp opened a new position in Kyverna Therapeutics (KYTX) in Q3 2026: 119 shares worth $809. The stake represents ﹤0.01% of the portfolio and ranks #4073 among its holdings. This is a return to the name: US Bancorp previously reported a position in KYTX as recently as Q4 2024.

US Bancorp first reported a position in KYTX in Q3 2024 and has held it in 3 quarters since. The position peaked at $17.2K in Q4 2024. 41 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

  • US Bancorp held 119 shares of Kyverna Therapeutics worth $809 as of Q3 2026.
  • Kyverna Therapeutics was a new US Bancorp position in Q3 2026.
  • Kyverna Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #4073 holding.
  • US Bancorp first reported a position in Kyverna Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • US Bancorp's Kyverna Therapeutics position peaked at $17.2K in Q4 2024.
  • 41 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.